Trusted Resources: Education
Scientific literature and patient education texts
Fetal Therapies and Trials for Lysosomal Storage Diseases: A Survey of Attitudes of Parents and Patients
source: Orphanet journal of rare diseases
year: 2022
authors: Schwab ME,Brown JEH,Lianoglou B,Jin C,Conroy PC,Gallagher RC,Harmatz P,MacKenzie TC
summary/abstract:Lysosomal storage diseases (LSDs) are inherited metabolic disorders that may lead to severe multi-organ disease. Current ERTs are limited by anti-drug antibodies, the blood-brain barrier, and early disease onset and progression before ERT is started. We have opened a phase I clinical trial of enzyme replacement therapy (ERT) for fetuses with LSDs (NCT04532047). We evaluated the attitudes of parents and patients with LSDs towards fetal clinical trials and therapies.
organization: Fetal Treatment Center, University of California, San Francisco, CA, USA.DOI: 10.1186/s13023-022-02178-z
read more
BookmarkRelated Content
-
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A SyndromeMucopolysaccharidosis type IVA (MPS IVA ...
-
Angle-Closure Glaucoma With Attenuated Mucopolysaccharidosis Type I in a Chinese FamilyMPS I is a metabolic disease that involv...
-
Drug Delivery for Neuronopathic Lysosomal Storage Diseases: Evolving Roles of the Blood Brain Barrier and Cerebrospi...Whereas significant strides have been ma...
-
Mucopolysaccharidoses Diagnosis in the Era of Enzyme Replacement Therapy in EgyptUndegraded glycosaminoglycans (GAGs) ind...
-
EMA Grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)JCR Pharmaceuticals Co., Ltd. announced ...
-
A Guide to Understanding MPS I (Hurler, Hurler-Scheie, and Scheie Syndromes)What Is MPS I? Mucopolysaccharidosis I (...
-
Combined Aortic and Mitral Valve Stenosis in Mucopolysaccharidosis Syndrome Type I-S: A Report of a Rare CaseMucopolysaccharidosis (MPS) syndrome is ...
Powered by
